IGF-1-LR3 is a recombinant analogue of insulin-like growth factor-1 with an extended N-terminal sequence and an arginine substitution. These structural modifications alter binding characteristics and pharmacological persistence. It remains primarily a research compound rather than an established human therapy, with limited clinical evidence and important uncertainties regarding safety, dosing, and long-term effects.